FindTrial
Sign In

CAL-101

DRUG3 trials

Sponsors

Gilead Sciences, German CLL Study Group

Conditions

Acute Myeloid Leukemia (AML)Allergic RhinitisChronic Lymphocytic LeucemiaChronic Lymphocytic Leukemia (CLL)Lymphoma, Non-Hodgkin (NHL)Multiple Myeloma (MM)

Phase 1

Dose Escalation Study of CAL-101 in Select Relapsed or Refractory Hematologic Malignancies
CompletedNCT00710528
Gilead SciencesAcute Myeloid Leukemia (AML), Chronic Lymphocytic Leukemia (CLL), Lymphoma, Non-Hodgkin (NHL) +1
Start: 2008-06-30End: 2012-08-31Updated: 2012-08-31
Study to Investigate Effects of CAL-101 in Subjects With Allergic Rhinitis Exposed to Allergen in an Environmental Chamber
CompletedNCT00836914
Gilead SciencesAllergic Rhinitis
Start: 2009-02-28End: 2009-03-31Updated: 2018-10-23

Phase 2

Sequential Regimen of Bendamustine-Debulking Followed by CAL-101 and GA101-Induction and -Maintenance in CLL (CLL2-BCG)
CompletedNCT02445131
German CLL Study GroupChronic Lymphocytic Leucemia
Start: 2015-05-28End: 2022-03-09Updated: 2024-05-09

Related Papers

Reassessing the chronic lymphocytic leukemia International Prognostic Index in the era of targeted therapies
Blood2024-04-1525 citations
CLL2-BXX Phase II trials: sequential, targeted treatment for eradication of minimal residual disease in chronic lymphocytic leukemia.
2018-02-2123 citations
Idelalisib Monotherapy and Durable Responses in Patients with Relapsed or Refractory Marginal Zone Lymphoma (MZL)
Blood2015-12-0318 citations
Idelalisib Monotherapy and Durable Responses in Patients with Relapsed or Refractory Small Lymphocytic Lymphoma (SLL)
Blood2015-12-035 citations
Patterns of Lymphocytosis in Patients with Chronic Lymphocytic Leukemia (CLL) or Small Lymphocytic Lymphoma (SLL) Treated with Idelalisib
Blood2015-12-03
Idelalisib monotherapy and durable responses in patients with relapsed or refractory Waldenstroms Macroglobulinemia (WM).
Journal of Clinical Oncology2015-05-206 citations
Idelalisib, an inhibitor of phosphatidylinositol 3-kinase p110δ, for relapsed/refractory chronic lymphocytic leukemia
Blood2014-03-11583 citations
A phase 1 study of the PI3Kδ inhibitor idelalisib in patients with relapsed/refractory mantle cell lymphoma (MCL)
Blood2014-03-11247 citations
Idelalisib, a selective inhibitor of phosphatidylinositol 3-kinase-δ, as therapy for previously treated indolent non-Hodgkin lymphoma
Blood2014-03-11206 citations